0
USD
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Cardiovascular Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Published Date: April 2019
|
Report Code: INFO-Othe-431
Home | Category |Business & Industrial |Pharmaceuticals & Biotech
Cardiovascular Drugs market Forecasts 2018 to 2024

Global Cardiovascular Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024

Code: INFO-Othe-431
Report
April 2019
93 Pages
Infoholic Research
Region: Asia Pacific, Europe, North America, Global,
Description
Table of Content
Tables & Figures

Global Cardiovascular Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Cardiovascular drugs are agents used for the treatment of diseases associated with the circulatory system, which include blood clots, stroke, coronary artery disease, variation in blood pressure, arrhythmias, high cholesterol, and heart failure. Increasing aging population, increasing prevalence of cardiovascular diseases, high incidence of obesity, and an unhealthy lifestyle are driving the demand for cardiovascular drugs. Complex drug development process and adverse effects of cardiovascular drugs are hampering the growth of the market. There is a constant increase in the incidence of cardiovascular diseases. According to WHO, in 2015, approximately 17.7 million people died due to various cardiovascular diseases. Increase in expenditure for R&D of novel cardiovascular drugs and increased government initiatives to raise the alertness of different types of cardiovascular conditions are expected to drive the market growth. Additionally, variation in lifestyle has increased the prevalence of the obesity, which has further led to the increase in the incidence of cardiovascular disorders globally. Nevertheless, the rigorous regulatory approval process for drugs, high treatment cost, and side effects related to cardiovascular drugs are hindering the progress of the market.
Market Analysis: The global cardiovascular drugs market is estimated to witness a CAGR of 2.8% during the forecast period 2018–2024. The market is analyzed based on two segments: product types and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share, followed by Europe, Asia Pacific, and Rest of the World. More than 60% of the market is occupied by North America, with the US being the major contributor to the market growth.
Product Analysis: Based on types, the market is segmented into anti-hypertensives, anti-hyperlipidemics, anticoagulants, antiarrhythmics, and others. Cardiac glycosides, antianginal drugs, anti-fibrinolytic, and anti-ischemic drugs are the other key product types in the market. The market is dominated by anti-hypertensives.
Key Players: Novartis AG, Sanofi, Bayer AG, Johnson & Johnson, Astra Zeneca PLC, and Pfizer are the key players in the market. The other prominent players in the market include Daiichi Sankyo, Inc., Bristol–Myers Squibb, GlaxoSmithKline plc, United Therapeutics Corp., Sun Pharmaceuticals, Eli Lilly and Company, Takeda Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, and Gilead Sciences, Inc.
Competitive Analysis: Mergers & acquisitions, approval of new drugs, and product launch are the primary strategies followed by various players in the market to increase their revenue. In March 2017, Espero Pharmaceuticals, Inc., a privately held company in commercial-stage cardiovascular pharmaceutical and Armetheon, Inc., a private company in late-clinical stage pharmaceutical have planned to merge. J&J, a major company in the cardiovascular drugs market established its footprints in this sector in 2008 with the approval of Xarelto in the US. Currently, in 2016, Xarelto earned revenue of ~$2.5 billion and is anticipated to rise to ~$3.5 billion by 2024. In January 2017, J&J acquired Actelion and added Uptravi & Opsumit to its portfolio, which are expected to secure the market leadership of the company. Warfarin by Epocrates, Inc. is struggling to maintain the market share from a stable rivulet of new products such as Xarelto, Pradaxa, Eliquis, and Savaysa.
Benefits: The report provides complete details about the usage and adoption rate of cardiovascular drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding the business in this market.

Table of Contents


1 Industry Outlook 10
1.1 Industry Overview 10
1.2 Industry Trends 10
1.3 Total Addressable Market (TAM) 11
2 Report Outline 14
2.1 Report Scope 14
2.2 Report Summary 14
2.3 Research Methodology 15
2.4 Report Assumptions 15
3 Market Snapshot 16
3.1 Market Definition – Infoholic Research 16
3.2 Segmented Addressable Market (SAM) 16
3.2.1 Trends of cardiovascular drugs market 16
3.3 Related Markets 17
3.3.1 Oncology (Cancer) Drugs 17
3.3.2 Active pharmaceutical ingredients (APIs) 18
3.3.3 Over the counter drugs (OTC) 18
3.3.4 Diabetes Drugs 19
4 Market Outline 20
4.1 Cardiovascular Drugs Approved by FDA (2011 – 2016) 20
4.2 Market Segmentation 21
4.3 Porter 5(Five) Forces 22
4.4 PEST Analysis 23
5 Market Characteristics 24
5.1 Market Dynamics 24
5.1.1 Drivers 24
5.1.1.1 Increasing Aging Population 24
5.1.1.2 Increasing prevalence of cardiovascular diseases 26
5.1.1.3 High Prevalence of Obesity 26
5.1.1.4 Unhealthy lifestyle 26
5.1.2 Opportunities 26
5.1.2.1 Increase merger and acquisitions 26
5.1.3 Restraints 27
5.1.3.1 Complex drug development process 27
5.1.3.2 Adverse effects of cardiovascular drugs 27
5.1.4 DRO – Impact Analysis 28
5.1.5 Key Stakeholders 29
6 Product Type: Market Size and Analysis 30
6.1 Overview 30
6.2 Anti-Hypertensives 31
6.3 Anti-Hyperlipidemics 32
6.4 Anti-Coagulants 33
6.5 Anti-Arrhythmic 34
6.6 Others 35
7 Regions: Market Size and Analysis 37
7.1 Overview 37
7.2 North America 39
7.2.1 Overview 39
7.2.2 United States 40
7.2.3 Canada 41
7.3 Europe 41
7.3.1 Overview 41
7.3.2 United Kingdom 42
7.3.3 Germany 43
7.4 APAC 43
7.4.1 Overview 43
7.4.2 India 44
7.4.3 China 44
7.4.4 Japan 45
7.5 Rest of the World 45
7.5.1 Overview 45
7.5.2 Africa 46
7.5.3 Brazil 46
8 Competitive Landscape 48
9 Vendor Profiles 50
9.1 Novartis AG 50
9.1.1 Overview 50
9.1.2 Business Unit 53
9.1.3 Geographic Presence 54
9.1.4 Business Focus 55
9.1.5 SWOT Analysis 55
9.1.6 Business Strategy 56
9.2 Sanofi 57
9.2.1 Overview 57
9.2.2 Geographic Revenue 60
9.2.3 Business Focus 60
9.2.4 SWOT Analysis 61
9.2.5 Business Strategy 61
9.3 Bayer AG 62
9.3.1 Overview 62
9.3.2 Business Unit 64
9.3.3 Geographic Presence 65
9.3.4 Business Focus 65
9.3.5 SWOT Analysis 66
9.3.6 Business Strategy 66
9.4 Johnson & Johnson 66
9.4.1 Overview 66
9.4.2 Business Units 70
9.4.3 Geographic Revenue 71
9.4.4 Business Focus 72
9.4.5 SWOT Analysis 73
9.4.6 Business Strategies 73
9.5 Astra Zenca PLC. 74
9.5.1 Overview 74
9.5.2 Geographic Presence 78
9.5.3 Business Focus 78
9.5.4 SWOT Analysis 78
9.5.5 Business Strategy 79
10 Companies to Watch For 80
10.1 Daiichi Sankyo, Inc. 80
10.1.1 Overview 80
10.1.2 Overview 80
10.2 Bristol-Myers Squibb 81
10.2.1 Overview 81
10.3 GlaxoSmithKline plc 83
10.3.1 Overview 83
10.4 United Therapeutics Corp 85
10.4.1 Overview 85
10.4.2 Highlights 85
10.5 Sun Pharmaceuticals. 86
10.5.1 Overview 86
10.5.2 Highlights 87
10.6 Eli Lilly and Company. 87
10.6.1 Overview 87
10.7 Takeda Pharmaceutical Co, Ltd 88
10.7.1 Overview 88
10.7.2 Highlights: 89
10.8 Boehringer Ingelheim GmbH 89
10.8.1 Overview 89
10.8.2 Highlights: 90
10.9 Gilead Sciences, Inc 90
10.9.1 Overview 90
10.9.2 Highlights: 91
Annexure 91
Abbreviations 91

List of Tables

TABLE 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY 12
TABLE 1 CARDIOVASCULAR DRUGS MARKET REVENUE BY TYPES, 2017–2024 ($BILLION) 31
TABLE 2 CARDIOVASCULAR DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($BILLION) 39
TABLE 3 NOVARTIS AG: OFFERINGS 50
TABLE 4 NOVARTIS AG: RECENT DEVELOPMENTS 50
TABLE 5 SANOFI: OFFERINGS 57
TABLE 6 SANOFI: RECENT DEVELOPMENTS 58
TABLE 7 BAYER AG: OFFERINGS 62
TABLE 8 BAYER AG: RECENT DEVELOPMENTS 62
TABLE 9 JOHNSON & JOHNSON: PRODUCT OFFERINGS 67
TABLE 10 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 67
TABLE 11 ASTRA ZENCA PLC: OFFERINGS 74
TABLE 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS 74
TABLE 13 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS 80
TABLE 14 BRISTOL-MYERS SQUIBB.: RECENT DEVELOPMENTS 81
TABLE 15 BRISTOL-MYERS SQUIBB.: KEY DEVELOPMENTS 81
TABLE 16 GLAXOSMITHKLINE PLC.: OVERVIEW 83
TABLE 17 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 84
TABLE 18 UNITED THERAPEUTICS CORP.: OVERVIEW 85
TABLE 19 SUN PHARMACEUTICALS: OVERVIEW 86
TABLE 20 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS 87
TABLE 21 TAKEDA PHARMACEUTICAL CO, LTD.: OVERVIEW 88
TABLE 22 BOEHRINGER INGELHEIM GMBH: OVERVIEW 89
TABLE 23 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 89
TABLE 24 GILEAD SCIENCES, INC.: OVERVIEW 91

List of Charts

CHART 1 GLOBAL CARDIOVASCULAR DISEASE MARKET 2017 ($BILLION) 12
CHART 2 RESEARCH METHODOLOGY OF GLOBAL CARDIOVASCULAR DRUGS MARKET 15
CHART 3 GLOBAL CARDIOVASCULAR DRUGS MARKET REVENUE, 2017-2024 ($BILLION) 17
CHART 4 NUMBER OF CARDIOVASCULAR DRUGS APPROVED FROM 2011-2016 21
CHART 5 SEGMENTATION OF GLOBAL CARDIOVASCULAR DRUGS MARKET 21
CHART 6 PORTER 5 FORCES OF CARDIOVASCULAR DRUGS MARKET 22
CHART 7 PEST ANALYSIS OF CARDIOVASCULAR DRUGS MARKET 23
CHART 8 MARKET DYNAMICS – DRO ANALYSIS 24
CHART 9 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%) 25
CHART 10 DRO – IMPACT ANALYSIS OF GLOBAL CARDIOVASCULAR DRUGS MARKET 28
CHART 11 KEY STAKEHOLDERS 29
CHART 12 CARDIOVSCULAR DRUGS MARKET BY PRODUCT TYPE SEGMENTATION, 2017-2024 ($BILLION) 30
CHART 13 ANTI-HYPERTENSIVES CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION) 32
CHART 14 ANTI-HYPERLIPIDEMICS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION) 33
CHART 15 ANTI-COAGULANTS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION) 34
CHART 16 ANTI-ARRHYTHMIC CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION) 34
CHART 17 OTHERS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION) 35
CHART 18 CARDIOVASCULAR DISEASES PREVALENCE WORLDWIDE IN MILLIONS (2015) 38
CHART 19 CARDIOVACULAR DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%) 38
CHART 20 CARDIOVASCULAR DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($BILLION) 39
CHART 21 CARDIOVASCULAR DRUGS MARKET REVENUE IN THE EUROPE REGION, 2017–2023 ($BILLION) 41
CHART 22 TYPE OF MEDICATION USED BY ADULTS WITH CARDIOVASCULAR DISEASE IN THE UK IN 2014 43
CHART 23 CARDIOVASCULAR DRUGS MARKET REVENUE IN THE APAC REGION, 2017–2023 ($BILLION) 45
CHART 24 CARDIOVASCULAR DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2023 ($BILLION) 46
CHART 25 NOVARTIS AG: OVERVIEW SNAPSHOT 52
CHART 26 NOVARTIS AG: BUSINESS UNITS 53
CHART 27 NOVARTIS GA: GEOGRAPHICAL PRESENCE 54
CHART 28 NOVARTIS AG: SWOT ANALYSIS 55
CHART 29 SANOFI SA: OVERVIEW SNAPSHOT 58
CHART 30 SANOFI SA: SEGMENTATION 59
CHART 31 SANOFI SA: GEOGRAPHIC REVENUE 60
CHART 32 SANOFI SA: SWOT ANALYSIS 61
CHART 33 BAYER AG: OVERVIEW SNAPSHOT 63
CHART 34 BAYER AG: BUSINESS UNITS 64
CHART 35 BAYER GA: GEOGRAPHICAL PRESENCE 65
CHART 36 BAYER AG: SWOT ANALYSIS 66
CHART 37 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 69
CHART 38 JOHNSON & JOHNSON: BUSINESS UNITS 70
CHART 39 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 71
CHART 40 JOHNSON & JOHNSON: SWOT ANALYSIS 73
CHART 41 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT 75
CHART 42 ASTRA ZENCA PLC: BUSINESS UNITS 77
CHART 43 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE 78
CHART 44 ASTRA ZENCA PLC: SWOT ANALYSIS 78

Global Cardiovascular Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Cardiovascular drugs are agents used for the treatment of diseases associated with the circulatory system, which include blood clots, stroke, coronary artery disease, variation in blood pressure, arrhythmias, high cholesterol, and heart failure. Increasing aging population, increasing prevalence of cardiovascular diseases, high incidence of obesity, and an unhealthy lifestyle are driving the demand for cardiovascular drugs. Complex drug development process and adverse effects of cardiovascular drugs are hampering the growth of the market. There is a constant increase in the incidence of cardiovascular diseases. According to WHO, in 2015, approximately 17.7 million people died due to various cardiovascular diseases. Increase in expenditure for R&D of novel cardiovascular drugs and increased government initiatives to raise the alertness of different types of cardiovascular conditions are expected to drive the market growth. Additionally, variation in lifestyle has increased the prevalence of the obesity, which has further led to the increase in the incidence of cardiovascular disorders globally. Nevertheless, the rigorous regulatory approval process for drugs, high treatment cost, and side effects related to cardiovascular drugs are hindering the progress of the market.
Market Analysis: The global cardiovascular drugs market is estimated to witness a CAGR of 2.8% during the forecast period 2018–2024. The market is analyzed based on two segments: product types and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share, followed by Europe, Asia Pacific, and Rest of the World. More than 60% of the market is occupied by North America, with the US being the major contributor to the market growth.
Product Analysis: Based on types, the market is segmented into anti-hypertensives, anti-hyperlipidemics, anticoagulants, antiarrhythmics, and others. Cardiac glycosides, antianginal drugs, anti-fibrinolytic, and anti-ischemic drugs are the other key product types in the market. The market is dominated by anti-hypertensives.
Key Players: Novartis AG, Sanofi, Bayer AG, Johnson & Johnson, Astra Zeneca PLC, and Pfizer are the key players in the market. The other prominent players in the market include Daiichi Sankyo, Inc., Bristol–Myers Squibb, GlaxoSmithKline plc, United Therapeutics Corp., Sun Pharmaceuticals, Eli Lilly and Company, Takeda Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, and Gilead Sciences, Inc.
Competitive Analysis: Mergers & acquisitions, approval of new drugs, and product launch are the primary strategies followed by various players in the market to increase their revenue. In March 2017, Espero Pharmaceuticals, Inc., a privately held company in commercial-stage cardiovascular pharmaceutical and Armetheon, Inc., a private company in late-clinical stage pharmaceutical have planned to merge. J&J, a major company in the cardiovascular drugs market established its footprints in this sector in 2008 with the approval of Xarelto in the US. Currently, in 2016, Xarelto earned revenue of ~$2.5 billion and is anticipated to rise to ~$3.5 billion by 2024. In January 2017, J&J acquired Actelion and added Uptravi & Opsumit to its portfolio, which are expected to secure the market leadership of the company. Warfarin by Epocrates, Inc. is struggling to maintain the market share from a stable rivulet of new products such as Xarelto, Pradaxa, Eliquis, and Savaysa.
Benefits: The report provides complete details about the usage and adoption rate of cardiovascular drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding the business in this market.

Read More

Table of Contents


1 Industry Outlook 10
1.1 Industry Overview 10
1.2 Industry Trends 10
1.3 Total Addressable Market (TAM) 11
2 Report Outline 14
2.1 Report Scope 14
2.2 Report Summary 14
2.3 Research Methodology 15
2.4 Report Assumptions 15
3 Market Snapshot 16
3.1 Market Definition – Infoholic Research 16
3.2 Segmented Addressable Market (SAM) 16
3.2.1 Trends of cardiovascular drugs market 16
3.3 Related Markets 17
3.3.1 Oncology (Cancer) Drugs 17
3.3.2 Active pharmaceutical ingredients (APIs) 18
3.3.3 Over the counter drugs (OTC) 18
3.3.4 Diabetes Drugs 19
4 Market Outline 20
4.1 Cardiovascular Drugs Approved by FDA (2011 – 2016) 20
4.2 Market Segmentation 21
4.3 Porter 5(Five) Forces 22
4.4 PEST Analysis 23
5 Market Characteristics 24
5.1 Market Dynamics 24
5.1.1 Drivers 24
5.1.1.1 Increasing Aging Population 24
5.1.1.2 Increasing prevalence of cardiovascular diseases 26
5.1.1.3 High Prevalence of Obesity 26
5.1.1.4 Unhealthy lifestyle 26
5.1.2 Opportunities 26
5.1.2.1 Increase merger and acquisitions 26
5.1.3 Restraints 27
5.1.3.1 Complex drug development process 27
5.1.3.2 Adverse effects of cardiovascular drugs 27
5.1.4 DRO – Impact Analysis 28
5.1.5 Key Stakeholders 29
6 Product Type: Market Size and Analysis 30
6.1 Overview 30
6.2 Anti-Hypertensives 31
6.3 Anti-Hyperlipidemics 32
6.4 Anti-Coagulants 33
6.5 Anti-Arrhythmic 34
6.6 Others 35
7 Regions: Market Size and Analysis 37
7.1 Overview 37
7.2 North America 39
7.2.1 Overview 39
7.2.2 United States 40
7.2.3 Canada 41
7.3 Europe 41
7.3.1 Overview 41
7.3.2 United Kingdom 42
7.3.3 Germany 43
7.4 APAC 43
7.4.1 Overview 43
7.4.2 India 44
7.4.3 China 44
7.4.4 Japan 45
7.5 Rest of the World 45
7.5.1 Overview 45
7.5.2 Africa 46
7.5.3 Brazil 46
8 Competitive Landscape 48
9 Vendor Profiles 50
9.1 Novartis AG 50
9.1.1 Overview 50
9.1.2 Business Unit 53
9.1.3 Geographic Presence 54
9.1.4 Business Focus 55
9.1.5 SWOT Analysis 55
9.1.6 Business Strategy 56
9.2 Sanofi 57
9.2.1 Overview 57
9.2.2 Geographic Revenue 60
9.2.3 Business Focus 60
9.2.4 SWOT Analysis 61
9.2.5 Business Strategy 61
9.3 Bayer AG 62
9.3.1 Overview 62
9.3.2 Business Unit 64
9.3.3 Geographic Presence 65
9.3.4 Business Focus 65
9.3.5 SWOT Analysis 66
9.3.6 Business Strategy 66
9.4 Johnson & Johnson 66
9.4.1 Overview 66
9.4.2 Business Units 70
9.4.3 Geographic Revenue 71
9.4.4 Business Focus 72
9.4.5 SWOT Analysis 73
9.4.6 Business Strategies 73
9.5 Astra Zenca PLC. 74
9.5.1 Overview 74
9.5.2 Geographic Presence 78
9.5.3 Business Focus 78
9.5.4 SWOT Analysis 78
9.5.5 Business Strategy 79
10 Companies to Watch For 80
10.1 Daiichi Sankyo, Inc. 80
10.1.1 Overview 80
10.1.2 Overview 80
10.2 Bristol-Myers Squibb 81
10.2.1 Overview 81
10.3 GlaxoSmithKline plc 83
10.3.1 Overview 83
10.4 United Therapeutics Corp 85
10.4.1 Overview 85
10.4.2 Highlights 85
10.5 Sun Pharmaceuticals. 86
10.5.1 Overview 86
10.5.2 Highlights 87
10.6 Eli Lilly and Company. 87
10.6.1 Overview 87
10.7 Takeda Pharmaceutical Co, Ltd 88
10.7.1 Overview 88
10.7.2 Highlights: 89
10.8 Boehringer Ingelheim GmbH 89
10.8.1 Overview 89
10.8.2 Highlights: 90
10.9 Gilead Sciences, Inc 90
10.9.1 Overview 90
10.9.2 Highlights: 91
Annexure 91
Abbreviations 91

Read More

List of Tables

TABLE 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY 12
TABLE 1 CARDIOVASCULAR DRUGS MARKET REVENUE BY TYPES, 2017–2024 ($BILLION) 31
TABLE 2 CARDIOVASCULAR DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($BILLION) 39
TABLE 3 NOVARTIS AG: OFFERINGS 50
TABLE 4 NOVARTIS AG: RECENT DEVELOPMENTS 50
TABLE 5 SANOFI: OFFERINGS 57
TABLE 6 SANOFI: RECENT DEVELOPMENTS 58
TABLE 7 BAYER AG: OFFERINGS 62
TABLE 8 BAYER AG: RECENT DEVELOPMENTS 62
TABLE 9 JOHNSON & JOHNSON: PRODUCT OFFERINGS 67
TABLE 10 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 67
TABLE 11 ASTRA ZENCA PLC: OFFERINGS 74
TABLE 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS 74
TABLE 13 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS 80
TABLE 14 BRISTOL-MYERS SQUIBB.: RECENT DEVELOPMENTS 81
TABLE 15 BRISTOL-MYERS SQUIBB.: KEY DEVELOPMENTS 81
TABLE 16 GLAXOSMITHKLINE PLC.: OVERVIEW 83
TABLE 17 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 84
TABLE 18 UNITED THERAPEUTICS CORP.: OVERVIEW 85
TABLE 19 SUN PHARMACEUTICALS: OVERVIEW 86
TABLE 20 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS 87
TABLE 21 TAKEDA PHARMACEUTICAL CO, LTD.: OVERVIEW 88
TABLE 22 BOEHRINGER INGELHEIM GMBH: OVERVIEW 89
TABLE 23 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 89
TABLE 24 GILEAD SCIENCES, INC.: OVERVIEW 91

List of Charts

CHART 1 GLOBAL CARDIOVASCULAR DISEASE MARKET 2017 ($BILLION) 12
CHART 2 RESEARCH METHODOLOGY OF GLOBAL CARDIOVASCULAR DRUGS MARKET 15
CHART 3 GLOBAL CARDIOVASCULAR DRUGS MARKET REVENUE, 2017-2024 ($BILLION) 17
CHART 4 NUMBER OF CARDIOVASCULAR DRUGS APPROVED FROM 2011-2016 21
CHART 5 SEGMENTATION OF GLOBAL CARDIOVASCULAR DRUGS MARKET 21
CHART 6 PORTER 5 FORCES OF CARDIOVASCULAR DRUGS MARKET 22
CHART 7 PEST ANALYSIS OF CARDIOVASCULAR DRUGS MARKET 23
CHART 8 MARKET DYNAMICS – DRO ANALYSIS 24
CHART 9 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%) 25
CHART 10 DRO – IMPACT ANALYSIS OF GLOBAL CARDIOVASCULAR DRUGS MARKET 28
CHART 11 KEY STAKEHOLDERS 29
CHART 12 CARDIOVSCULAR DRUGS MARKET BY PRODUCT TYPE SEGMENTATION, 2017-2024 ($BILLION) 30
CHART 13 ANTI-HYPERTENSIVES CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION) 32
CHART 14 ANTI-HYPERLIPIDEMICS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION) 33
CHART 15 ANTI-COAGULANTS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION) 34
CHART 16 ANTI-ARRHYTHMIC CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION) 34
CHART 17 OTHERS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION) 35
CHART 18 CARDIOVASCULAR DISEASES PREVALENCE WORLDWIDE IN MILLIONS (2015) 38
CHART 19 CARDIOVACULAR DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%) 38
CHART 20 CARDIOVASCULAR DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($BILLION) 39
CHART 21 CARDIOVASCULAR DRUGS MARKET REVENUE IN THE EUROPE REGION, 2017–2023 ($BILLION) 41
CHART 22 TYPE OF MEDICATION USED BY ADULTS WITH CARDIOVASCULAR DISEASE IN THE UK IN 2014 43
CHART 23 CARDIOVASCULAR DRUGS MARKET REVENUE IN THE APAC REGION, 2017–2023 ($BILLION) 45
CHART 24 CARDIOVASCULAR DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2023 ($BILLION) 46
CHART 25 NOVARTIS AG: OVERVIEW SNAPSHOT 52
CHART 26 NOVARTIS AG: BUSINESS UNITS 53
CHART 27 NOVARTIS GA: GEOGRAPHICAL PRESENCE 54
CHART 28 NOVARTIS AG: SWOT ANALYSIS 55
CHART 29 SANOFI SA: OVERVIEW SNAPSHOT 58
CHART 30 SANOFI SA: SEGMENTATION 59
CHART 31 SANOFI SA: GEOGRAPHIC REVENUE 60
CHART 32 SANOFI SA: SWOT ANALYSIS 61
CHART 33 BAYER AG: OVERVIEW SNAPSHOT 63
CHART 34 BAYER AG: BUSINESS UNITS 64
CHART 35 BAYER GA: GEOGRAPHICAL PRESENCE 65
CHART 36 BAYER AG: SWOT ANALYSIS 66
CHART 37 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 69
CHART 38 JOHNSON & JOHNSON: BUSINESS UNITS 70
CHART 39 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 71
CHART 40 JOHNSON & JOHNSON: SWOT ANALYSIS 73
CHART 41 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT 75
CHART 42 ASTRA ZENCA PLC: BUSINESS UNITS 77
CHART 43 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE 78
CHART 44 ASTRA ZENCA PLC: SWOT ANALYSIS 78

Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$2750
This license allows only one user to access the PDF.

Site License

Electronic (PDF)
$3500
This license allows all the users of an enterprise residing in one location to access the PDF

Enterprise License

Electronic (PDF)
$4500
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Novocure

RELATED REPORTS

Global Anosmia Market Size Status and Forecast 2021 2027
Global Anosmia Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-27U4147
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Epidermal Growth Factor EGF CAS 62253 63 8 Market Research Report 2021
Global Epidermal Growth Factor (EGF) (CAS 62253-63-8) Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-2Y4709
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Catechin Market Research Report 2021
Global Catechin Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-39V4149
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

0 Items
X
No items in the cart.
$0.0